Kadmon Holdings Inc (NASDAQ:KDMN) has earned an average recommendation of “Hold” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $8.92.

A number of analysts have recently weighed in on KDMN shares. Piper Jaffray Companies set a $7.00 price objective on shares of Kadmon Holdings and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Kadmon Holdings in a research note on Monday, June 26th. Zacks Investment Research upgraded shares of Kadmon Holdings from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Tuesday, June 20th. Finally, ValuEngine cut shares of Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/11/kadmon-holdings-inc-nasdaqkdmn-given-consensus-recommendation-of-hold-by-analysts.html.

Shares of Kadmon Holdings (KDMN) traded down 2.26% during trading on Friday, hitting $2.16. 257,385 shares of the stock were exchanged. The stock’s 50 day moving average is $3.09 and its 200-day moving average is $3.18. Kadmon Holdings has a 12-month low of $2.05 and a 12-month high of $10.48. The stock’s market cap is $111.99 million.

Kadmon Holdings (NASDAQ:KDMN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The firm had revenue of $3 million during the quarter, compared to analyst estimates of $3.46 million. During the same quarter in the previous year, the firm posted ($4.40) earnings per share. Kadmon Holdings’s quarterly revenue was down 53.1% compared to the same quarter last year. Equities research analysts anticipate that Kadmon Holdings will post ($1.58) EPS for the current year.

In related news, major shareholder Goldentree Asset Management Lp sold 64,375 shares of the company’s stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $4.04, for a total transaction of $260,075.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have purchased 14,707 shares of company stock valued at $34,294 and have sold 1,840,331 shares valued at $6,193,607.

Institutional investors have recently added to or reduced their stakes in the stock. KCG Holdings Inc. bought a new position in Kadmon Holdings during the first quarter valued at approximately $124,000. Renaissance Technologies LLC bought a new position in Kadmon Holdings during the first quarter valued at approximately $158,000. Bank of New York Mellon Corp boosted its position in Kadmon Holdings by 302.3% in the first quarter. Bank of New York Mellon Corp now owns 46,304 shares of the company’s stock valued at $167,000 after buying an additional 34,794 shares during the last quarter. Wells Fargo & Company MN boosted its position in Kadmon Holdings by 84.8% in the first quarter. Wells Fargo & Company MN now owns 51,291 shares of the company’s stock valued at $186,000 after buying an additional 23,541 shares during the last quarter. Finally, Nationwide Fund Advisors bought a new position in Kadmon Holdings during the first quarter valued at approximately $192,000.

Kadmon Holdings Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Analyst Recommendations for Kadmon Holdings (NASDAQ:KDMN)

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.